Vera Therapeutics completed full enrolment in its pivotal trial of atacicept in IgA nephropathy and Minovia Therapeutics received …
Vera Therapeutics completed full enrolment in its pivotal trial of atacicept in IgA nephropathy and Minovia Therapeutics received …
Clinical-stage companies AC Immune and Edgewise Therapeutics shared encouraging updates on their immunotherapy and cardiac medicine programs, signaling …
In a shareholder letter released on 1 April 2025, MAIA Biotechnology revealed plans to advance telomere‐targeted therapies in …
MaaT Pharma advances its microbiome ecosystem therapies with new preclinical evidence showing enhanced patient immunotherapy responses.
Experimental gene-silencing drug lepodisiran delivers long-lasting reduction of cardiovascular risk factor, while Spinogenix launches trial for novel synaptic …
The sudden departure of FDA’s Peter Marks raises uncertainty across the biopharma sector amid ongoing regulatory scrutiny and …
Alnylam’s Fitusiran gains FDA approval as a first RNAi therapeutic for hemophilia, while Vertex discontinues its innovative insulin-producing …
The FDA approval of Alnylam’s Fitusiran marks a milestone in RNA interference therapeutics, while Vertex discontinues a novel …
MaaT Pharma strengthens financial position to advance its microbiome-based therapies, focusing on acute graft-versus-host disease and hemato-oncology indications.
Viking Therapeutics and Bluejay Therapeutics highlight progress in obesity management and neurological disease treatment with key clinical milestones.